Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jul 27;20(1):154.
doi: 10.1186/s12933-021-01344-0.

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

Ofri Mosenzon  1 , Abdullah Alguwaihes  2 , Jose Luis Arenas Leon  3 , Fahri Bayram  4 , Patrice Darmon  5 , Timothy M E Davis  6 , Guillermo Dieuzeide  7 , Kirsten T Eriksen  8 , Tianpei Hong  9 , Margit S Kaltoft  8 , Csaba Lengyel  10 , Nicolai A Rhee  11 , Giuseppina T Russo  12 , Shinichiro Shirabe  13 , Katerina Urbancova  14 , Sergio Vencio  15 ; CAPTURE Study Investigators
Affiliations
Multicenter Study

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

Ofri Mosenzon et al. Cardiovasc Diabetol. .

Abstract

Background: There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and its management in adults with T2D across 13 countries from five continents. Additional objectives were to further characterize the study sample regarding demographics, clinical parameters and medication usage, with particular reference to blood glucose-lowering agents (GLAs: glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) with demonstrated cardiovascular benefit in randomized intervention trials.

Methods: Data were collected from adults with T2D managed in primary or specialist care in Australia, China, Japan, Czech Republic, France, Hungary, Italy, Argentina, Brazil, Mexico, Israel, Kingdom of Saudi Arabia, and Turkey in 2019, using standardized methodology. CVD prevalence, weighted by diabetes prevalence in each country, was estimated for the overall CAPTURE sample and participating countries. Country-specific odds ratios for CVD prevalence were further adjusted for relevant demographic and clinical parameters.

Results: The overall CAPTURE sample included 9823 adults with T2D (n = 4502 from primary care; n = 5321 from specialist care). The overall CAPTURE sample had median (interquartile range) diabetes duration 10.7 years (5.6-17.9 years) and glycated hemoglobin 7.3% (6.6-8.4%) [56 mmol/mol (49-68 mmol/mol)]. Overall weighted CVD and atherosclerotic CVD prevalence estimates were 34.8% (95% confidence interval [CI] 32.7-36.8) and 31.8% (95% CI 29.7-33.8%), respectively. Age, gender, and clinical parameters accounted for some of the between-country variation in CVD prevalence. GLAs with demonstrated cardiovascular benefit were used by 21.9% of participants, which was similar in participants with and without CVD: 21.5% and 22.2%, respectively.

Conclusions: In 2019, approximately one in three adults with T2D in CAPTURE had diagnosed CVD. The low use of GLAs with demonstrated cardiovascular benefit even in participants with established CVD suggested that most were not managed according to contemporary diabetes and cardiology guidelines. Study registration NCT03786406 (registered on December 20, 2018), NCT03811288 (registered on January 18, 2019).

Keywords: Atherosclerotic cardiovascular disease; Cardiovascular disease; Glucagon-like peptide-1 receptor agonists; Non-interventional study; Prevalence; Sodium-glucose co-transporter-2 inhibitors; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Ofri Mosenzon reports advisory board membership from Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, AstraZeneca, and BOL Pharma; speaker’s bureau honorarium from AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, and Janssen; and research grants from Novo Nordisk and AstraZeneca. Abdullah Alguwaihes reports speaker’s bureau honoraria and advisory board membership from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; in addition to research support from AstraZeneca and Novo Nordisk. Jose Luis Arenas Leon reports advisory board membership from Novo Nordisk, AstraZeneca, Merck Sharp & Dohme, and Novartis; speakers bureau honorarium from Novo Nordisk, AstraZeneca, Merck Sharp & Dohme, and Merck; and research grants from Novo Nordisk, AstraZeneca, Amgen, Merck Sharp & Dohme, Novartis, Sanofi, Takeda, Janssen, and Bristol Myers Squibb. Fahri Bayram reports speaker honoraria and travel sponsorship from Bilim İlaç, Abbott, Novo Nordisk, Sanofi Genzyme, Pfizer, and Eczacıbaşı İlaç; advisory board and consultancy for Novo Nordisk, Sanofi Genzyme, Abbott, Pfizer, and Bilim İlaç; and participation in clinical trials for Novo Nordisk, Lilly, Sanofi, and Abbott. Patrice Darmon reports honoraria, consultancy, advisory role, lectures, or travel grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Novartis, Novo Nordisk, Sanofi, Mundipharma, and Abbott. Timothy M.E. Davis reports speaker’s bureau honoraria and advisory board membership from Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi; and speaker’s bureau honorarium from Boehringer Ingelheim and AstraZeneca. Guillermo Dieuzeide reports speaker`s bureau honoraria, advisory board membership, and grants from AstraZeneca, Novo Nordisk, Sanofi Aventis, and Roche Diagnosis. Kristen T. Eriksen Margit S. Kaltoft and Nicolai A. Rhee are employees of Novo Nordisk; Margit S. Kaltoft and Nicolai A. Rhee also own stock and/or shares in Novo Nordisk. Tianpei Hong reports speaker’s bureau honoraria and advisory board membership from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi. Csaba Lengyel reports honoraria and travel grants from AstraZeneca, Berlin Chemie/A Menarini, Boehringer Ingelheim, EGIS, KRKA, Lilly Hungária Kft., MSD Pharma, Novartis, Novo Nordisk, Pfizer, Richter Gedeon, Sandoz, Sanofi Aventis, Servier, TEVA, and Wörwag Pharma. Giuseppina T. Russo reports speaker’s bureau honoraria and advisory board membership from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi. Shinichiro Shirabe reports honoraria from Novo Nordisk Pharma Ltd., Sumitomo Dainippon Pharma, and Merck Sharp & Dohme. Katherine Urbancova has worked on oral presentations, articles, and advisory boards for Novo Nordisk, Sanofi Aventis, Boehringer Ingelheim, Novartis, Eli Lilly, and Merck. Sergio Vencio reports research or educational grants from Novartis, Novo Nordisk, Boehringer Ingelheim, and Biomm.

Figures

Fig. 1
Fig. 1
Weighted CVD prevalence in people with type 2 diabetes across the 13 countries. Data presented overall and by country. Overall prevalence estimate (across the 13 countries) calculated as a weighted estimate to account for the size of the diabetes population of each country [26] and represented by the grey dotted line. Both the overall and country-level prevalence estimates were weighted by the sampling of participants by healthcare setting, if it was different from as planned. n numbers are the crude number of participants with CVD (i.e. they were not weighted). CI confidence interval, CVD cardiovascular disease, KSA Kingdom of Saudi Arabia, n number of participants with CVD
Fig. 2
Fig. 2
Overall weighted CVD prevalence in people with type 2 diabetes by CVD subtype and diagnosis. Data are overall prevalence estimates (95% CI), which were calculated as weighted estimates to account for the size of the diabetes population of each country [26] and the sampling of participants by healthcare setting, if it was different from as planned. Along the y-axis, CVD subtypes are in bold font, while the diagnoses contributing to each subtype are in plain font. Diagnoses are not mutually exclusive; one participant may have multiple diagnoses. *Categorized as ASCVD. †Included conduction abnormalities. ASCVD atherosclerotic CVD, AV atrioventricular, CHD coronary heart disease, CI confidence interval, CVD cardiovascular disease, PAD peripheral artery disease, SND sinus node dysfunction
Fig. 3
Fig. 3
Use of a GLAs, b GLAs with demonstrated CV benefit and c selected CV medications. Data are % and were not weighted. Data are presented for the CAPTURE study sample overall and stratified by CVD status. In b, GLAs with demonstrated CV benefit were defined per 2020 American Diabetes Association guidelines [19] as GLP-1 RAs: dulaglutide, liraglutide, and semaglutide; and SGLT2is: canagliflozin, dapagliflozin, and empagliflozin. ACE angiotensin-converting enzyme, AGI alpha glucosidase inhibitor, ARB angiotensin II receptor blocker, CV cardiovascular, CVD cardiovascular disease, DPP-4i dipeptidyl peptidase-4 inhibitor, GLA blood glucose-lowering agent, GLP-1 RA glucagon-like peptide-1 receptor agonist, SGLT2i sodium-glucose co-transporter-2 inhibitor, SU sulfonylurea, TZD thiazolidinedione
See this image and copyright information in PMC

References

    1. Gerstein HC. Diabetes: dysglycaemia as a cause of cardiovascular outcomes. Nat Rev Endocrinol. 2015;11:508–510. doi: 10.1038/nrendo.2015.118. - DOI - PubMed
    1. International Diabetes Federation: IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation; 2019.
    1. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222. doi: 10.1016/S0140-6736(10)60484-9. - DOI - PMC - PubMed
    1. Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41. doi: 10.1056/NEJMoa1008862. - DOI - PMC - PubMed
    1. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323. doi: 10.1093/eurheartj/ehz486. - DOI - PubMed

Publication types

Substances

Associated data